Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 406

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 406
---
.19 |                 €79.17 |
| Of which with market condition                                                               |              1,616,643 |                 90,451 |              1,413,387 |                 64,185 |              1,343,805 |                 99,646 |
| Fair value per share awarded other than to the ChiefExecutive Officer(c)                     |                 €72.79 |                 €75.11 |                 €83.74 |                 €74.50 |                 €86.65 |                 €69.60 |
| Fair value per share awarded other than to the ChiefExecutive Officer - additional shares(d) |                 €13.50 |                 €32.09 |                 €43.60 |                 €34.90 |                 €49.00 |                 €54.70 |
| Fair value per share awarded to the Chief ExecutiveOfficer(c)                                |                 €72.38 |                      — |                 €82.17 |                      — |                 €84.46 |                      — |
| Fair value of plan at the date of grant(€ million)                                           |                    346 |                      7 |                    326 |                      5 |                    294 |                      8 |

(a) Includes shares awarded in an additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and

8,229 awarded in December 2024 (versus 121,097 awarded in May 2023 and 5,838 awarded in December 2023 ).

(b) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.

(c) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for

dividends expected during the vesting period.

(d) Additional tranche subject to a higher level of market conditions: 139,665 additional shares awarded in April 2024 and 8,229 awarded in

December 2024 (versus 121,097 awarded in May 2023 , 5,838 awarded in December 2023 , 114,874 awarded in May 2022 and 9,066 awarded in

December 2022 ).

The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in

the table below:

|                                                         |    2024(a) |